Trending

BI

Boehringer buys immunotherapy biotech AMAL Therapeutics

Boehringer buys immunotherapy biotech AMAL Therapeutics

Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and

X

Boehringer buys immunotherapy biotech AMAL Therapeutics

https://pharmaphorum.com/news/boehringer-buys-immunotherapy-biotech-amal-therapeutics/

Boehringer and Sarah Cannon team for immune-oncology venture

Boehringer and Sarah Cannon team for immune-oncology venture

Partnership will seek to develop two immune checkpoint inhibitor candidates.

X

Boehringer and Sarah Cannon team for immune-oncology venture

https://pharmaphorum.com/news/boehringer-sarah-cannon-team-immune-oncology-venture/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com